Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Comprehensive Review of HER2 in Cancer Biology and Therapeutics
Xiaoqing Cheng
Genes (2024) Vol. 15, Iss. 7, pp. 903-903
Open Access | Times Cited: 19

Showing 19 citing articles:

Oncology: What You May Have Missed in 2024
Zainab Ali Amer Al Maqrashi, Sze Wah Samuel Chan, Zeba Siddiqui, et al.
Annals of Internal Medicine (2025)
Closed Access | Times Cited: 1
LMAN2 interacts with HEATR3 to expedite HER2-positive breast cancer advancement and inflammation and Akt/ERK/NF-κB signaling
Sujian Xiao, Tong Yu, Fulan Yang, et al.
Biochemistry and Cell Biology (2025)
Closed Access
Design, and Evaluation of In-Silico Anti-cancer Activity of Novel Gefitinib Analogues Against 21 Target Proteins
Supriti Khan Ushna, Ananta Kumar Das
Deleted Journal (2025), pp. 100030-100030
Closed Access
Incidência crescente de câncer de mama em mulheres entre 40 e 49 anos no Brasil (2014-2023)
Tuany Caroline Bernardi, Maria Luiza Paes Carpine, Mariane Fantinelli Venarusso, et al.
Cuadernos de Educación y Desarrollo (2025) Vol. 17, Iss. 2, pp. e7468-e7468
Closed Access
Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer
María Elena Lacruz, Svenja Thies, Andrea Schmidt‐Pokrzywniak, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access
Targeting HER2 in metastatic urothelial carcinoma: a contemporary review
Albert Jang, Nirmala Ghimirey, Hamsa L.S. Kumar, et al.
ONCOLOGIE (2025)
Closed Access
Harnessing the Human Microbiome and its Impact on Immuno-Oncology and Nanotechnology for Next-Generation Cancer Therapies
Mamali Das, Chandramohan Kiruthiga, Rajamohamed Beema Shafreen, et al.
European Journal of Pharmacology (2025) Vol. 996, pp. 177436-177436
Closed Access
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study
John V. Heymach, Frans L. Opdam, Minal Barve, et al.
Journal of Clinical Oncology (2025)
Closed Access
The role of genetics and epigenetics in breast cancer: A comprehensive review of metastasis, risk factors, and future perspectives
Yimeng Chai, Yao Shi
Journal of Pharmaceutical Analysis (2025), pp. 101268-101268
Open Access
Affibody-based HER2 prodrug shows conditional cytotoxic effect on HER2-positive cancer cells
Cornelia Westerberg, Anna Mestre Borras, Stefan Ståhl, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151660-151660
Open Access
Interaction between redox regulation, immune activation, and response to treatment in HER2+ breast cancer
Paulo Luz, Sofı́a Ramos, Maria José Oliveira, et al.
Redox Biology (2025), pp. 103609-103609
Open Access
Therapeutic potential of microRNA-506 in cancer treatment: mechanisms and therapeutic implications
Sha Mao, Junyan Li, Jiahui Huang, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Discovery of New HER2 Inhibitors via Computational Docking, Pharmacophore Modeling, and Machine Learning
Aseel Yasin Matrouk, Haneen Mohammad, Safa Daoud, et al.
Molecular Informatics (2025) Vol. 44, Iss. 2
Closed Access
Prognostic and Predictive Significance of Primary Tumor Localization and HER2 Expression in the Treatment of Patients with KRAS Wild-Type Metastatic Colorectal Cancer: Single-Centre Experience from Serbia
Jelena Radić, Ivan Nikolić, Ivana Kolarov-Bjelobrk, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 8, pp. 879-879
Open Access | Times Cited: 2
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Dai Okemoto, Toshifumi Yamaguchi, Mariko Yamaguchi, et al.
Case Reports in Oncology (2024) Vol. 17, Iss. 1, pp. 1001-1007
Open Access
The Prospective role of lapatinib as an adjuvant therapy in prevalent cancers: Insights from in silico analysis targeting EGFR and HER2
Behnaz Dolatabadi, Maryam Peymani, Leila Rouhi, et al.
Molecular and Cellular Probes (2024) Vol. 78, pp. 101985-101985
Open Access
A review of recombinant HER3 affibodies with an effective diagnostic view of cancer cells
Sahar Babaei Khorzoughi, Mehrnoosh Tavakoli, Mojtaba Mortazavi, et al.
Journal of drug targeting (2024), pp. 1-12
Closed Access
PU-H71 (NSC 750424): a molecular masterpiece that targets HSP90 in cancer and beyond
Sameh Saber, Rasha Abdelhady, Mai A. Elhemely, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access
Pyrotinib induces cell death in HER2-positive breast cancer via triggering HSP90-dependent HER2 degradation and ROS/HSF-1-dependent oxidative DNA damage
Xiaomin Gao, Xu Guo, Wenbo Yuan, et al.
Cell Stress and Chaperones (2024)
Open Access
Page 1

Scroll to top